Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment.
Lucemyra (lofexidine hydrochloride), now approved by the Food and Drug Administration, may offer relief (and new hope) for patients experiencing withdrawal symptoms from opioid dependence.
The first-ever preventative treatment for migraine in adults, Aimovig (erenumab-aooe) is now approved by the Food and Drug Administration.
New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.
A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.
This will provide a much-needed alternative therapy for a debilitating disease with limited treatment options.
Moderately to severely active ulcerative colitis can now be treated with Xeljanz (tofacitinib), following the expanded approval by the Food and Drug Administration (FDA). This will provide a much-needed alternative therapy for a debilitating disease with limited treatment options.
"We currently test for liver cancer using ultrasound and a blood protein marker called alpha fetoprotein," says John Kisiel, M.D., a gastroenterologist at Mayo Clinic. "Unfortunately, these tests are not very sensitive for curable stage liver cancers, and most patients who need this testing do not have it easily available or [are] not able to receive it often enough to be effective." The new advance by the team opens the door to further development of a DNA test.
This new development may increase chances of patients discussing the disease with their doctor...
A new package insert that includes information/data about psoriasis in the genital area has been approved by the Food and Drug Administration (FDA).
Men with metastatic castration-resistant prostate cancer (mCRPC) may have a new course of treatment available to them.